Enochian BioSciences Announces Findings From A Rigorous Internal Review of Scientific Data
July 01, 2022 17:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, July 01, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)—In recent days, Enochian BioSciences (the Company) has conducted a rigorous internal review of scientific data to give partners and...
Scientific Leaders Agree on Promise of Enochian BioSciences
May 31, 2022 08:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) - Enochian BioSciences is working to solve our greatest public health threats like HIV, cancer, and coronavirus. The company’s underlying...
Enochian BioSciences Board Learns of Arrest of Co-Founder and Inventor and Expresses Strong Confidence in the Promising Future of the Company
May 25, 2022 16:20 ET
|
Enochian BioSciences, Inc.
The Board learned of the arrest of Dr. Serhat Gumrukçu after the Press Release by the Department of Justice on May 25, 2022;The Board has verified that the incident leading to the arrest occurred...
Enochian BioSciences Announces the Appointment of Executive Vice President of Research and Development with 25 years of Industry Experience
April 20, 2022 07:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, April 20, 2022 (GLOBE NEWSWIRE) -- Enochian BioSciences (NASDAQ: ENOB). Enochian BioSciences Inc., a company focused on gene-modified cellular and immunotherapies in infectious diseases...
Enochian BioSciences Announces Appointment of Senior Vice President for Clinical Operations with 32 Years’ Experience at Pfizer
April 07, 2022 06:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, April 07, 2022 (GLOBE NEWSWIRE) -- Enochian BioSciences, Inc., (NASDAQ: ENOB), a company focused on gene-modified cellular and immunotherapies in infectious diseases and cancer,...
Enochian BioSciences Inventor and Co-Founder Presents Data on Novel Clinical Approaches as the Invited, Concluding Plenary Speaker at the Innate Killer Summit
April 05, 2022 06:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, April 05, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene-modified cellular and immune therapies for infectious diseases and cancer, announced...
Enochian BioSciences and Caring Cross Announce a Partnership to Potentially Increase the Effectiveness of a CAR-T Approach for HIV Cure Currently Being Studied in Humans
March 15, 2022 07:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, March 15, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, has...
Enochian BioSciences Announces Scientific Presentation at World Vaccine Conference on Promising Human and Laboratory Data to Potentially Treat Solid Tumors
December 03, 2021 07:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, Dec. 03, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...
Enochian BioSciences Announces the Successful Completion of an FDA Pre-IND for a Potential Cure for HIV: The Second Pre-IND in 1 month
October 18, 2021 07:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, Oct. 18, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today...
Scientific Advisory Board Member Resigns Due to Conflict with Responsibilities with Important Public Sector Entity
October 15, 2021 18:00 ET
|
Enochian BioSciences, Inc.
LOS ANGELES, Oct. 15, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, announced...